Nivolumab-relatlimab

DRUG2 trials

Sponsors

Iovance Biotherapeutics, Inc., Memorial Sloan Kettering Cancer Center

Conditions

MelanomaMetastatic MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck

Phase 2

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

RecruitingNCT03645928

Iovance Biotherapeutics, Inc.Metastatic Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck

Start: 2019-05-07End: 2029-08-09Target: 245Updated: 2025-06-19

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Active, not recruitingNCT05912244

Memorial Sloan Kettering Cancer CenterMelanoma

Start: 2023-06-09End: 2027-06-09Updated: 2026-02-17

Related Papers

Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.

Journal of Clinical Oncology2025-05-281 citations

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.

Journal of Clinical Oncology2024-06-0114 citations

A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma.

Journal of Clinical Oncology2024-06-011 citations

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer

Future Oncology2023-05-185 citations

Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy.

Journal of Clinical Oncology2022-06-014 citations

492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers

Regular and Young Investigator Award Abstracts2021-11-0134 citations

458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)

Regular and Young Investigator Award Abstracts2021-11-0124 citations

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for ImmunoTherapy of Cancer2021-10-0161 citations

Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors

Cancer Research2021-07-011 citations

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

Journal of Clinical Oncology2021-05-201 citations

353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC

Regular and Young Investigator Award Abstracts2020-11-0115 citations

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

Journal for ImmunoTherapy of Cancer2020-07-0153 citations

A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.

Journal of Clinical Oncology2019-05-205 citations

A phase II study of autologous tumor infiltrating lymphocytes (TIL; LN-144/LN-145) in patients with solid tumors

Annals of Oncology2018-12-01